Delivery Order SPE2DB22D2006-SPE2DB25FW2QX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,759.20 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit-dose packaging on September 16, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 17, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a $13,431.90 delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets on April 24, 2025, with completion targeted for April 25, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,514.77 for UBRELVY 50 mg tablets (UD 10s) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is an acute migraine treatment medication, representing one of numerous pharmaceutical products supplied...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets, with a ceiling value of $1,937.86. The award, issued on September 3, 2025, represents a firm fixed price delivery order with an ultimate completion date of September 4, 2025. This contract was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of UBRELVY (ubrogepant) 50 mg tablets in unit dose packaging of 10 tablets each, with a ceiling value of $3,085.51. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, executed under a competitive, non-set-aside procurement process. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $16,964.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (10-count). The contract, which is a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, has an ultimate completion date of September 11, 2025. UBRELVY is an FDA-approved acute migraine treatment...
- The Defense Logistics Agency awarded a $3,413.91 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10s. This is a non-set-aside competitive award with a completion date of August 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is an acute treatment medication for migraine headaches, representing routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 units, with a ceiling value of $18,754.48. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 10, 2025. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (Ubrogepant) 100 mg tablets, unit dose packages of 10, valued at $1,158.25 with a firm fixed price structure. This award, issued on July 21, 2025, represents a non-set-aside competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the contractor's distribution facility in Conshohocken,...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW2QXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,093.52 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract reflects no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. UBRELVY is an acute migraine treatment medication, representing one of numerous pharmaceutical products that AmerisourceBergen delivers through its federal contracts. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026. As a prime vendor to the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen serves critical federal healthcare customers including the Defense Health Agency, U.S. Coast Guard, and military medical systems globally, providing an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's consistent receipt of competitive, firm fixed-price delivery orders demonstrates its established capability to fulfill federal medical procurement requirements efficiently.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 7/18/25 |